Pei F

No ORCID on file · 4 papers in corpus · active 2024-2026

Study types

  • article 2
  • other 2

Condition tags

  • endometriosis 3
article 2026
Luoshi Neiyi prescription mitigates endometriosis by modulating nuclear receptor subfamily 5 group A member 1 methylation
International journal of biological macromolecules ·doi:10.1016/j.ijbiomac.2026.153016

OBJECTIVE: This study aimed to investigate the mechanisms underlying Nuclear Receptor Subfamily 5 Group A Member 1 (NR5A1, encoding SF-1) hypomethylation in endometriosis (EMs) and to evaluate the effects of Luoshi Neiyi Prescription (LSNYP…

other 2026
Mechanisms of Luoshi Neiyi prescription (LSNYP) in endometriosis: a network pharmacology and experimental study
Hereditas ·doi:10.1186/s41065-026-00637-2

BACKGROUND: Luoshi Neiyi prescription (LSNYP) is a traditional Chinese medicine that has a clinical effect on endometriosis (EMs). This study combined network pharmacology with experimental validation to explore its potential molecular mech…

article 2024
Luoshi Neiyi Prescription inhibits estradiol synthesis and inflammation in endometriosis through the HIF1A/EZH2/SF-1 pathway
Journal of ethnopharmacology ·doi:10.1016/j.jep.2024.118659

ETHNOPHARMACOLOGICAL RELEVANCE: Endometriosis (EMS) is a common gynecological disease that causes dysmenorrhea, chronic pelvic pain and infertility. Luoshi Neiyi Prescription (LSNYP), a traditional Chinese medicine (TCM) formula, is used to…

other 2024
Potential mechanism of Luoshi Neiyi prescription in endometriosis based on serum pharmacochemistry and network pharmacology
Frontiers in pharmacology ·doi:10.3389/fphar.2024.1395160

INTRODUCTION: Endometriosis (EMs) is characterized by ectopic growth of active endometrial tissue outside the uterus. The Luoshi Neiyi prescription (LSNYP) has been extensively used for treating EMs in China. However, data on the active che…